Kane Biotech Will Attend Las Vegas Wound Care Summit
The company will present clinical data and showcase its revyve product line in Las Vegas from October 15-18, 2026.
Updated on Oct. 7, 2026 in Biotech
Live Poll
Do you believe healthcare companies are prioritizing patient access when expanding into new regional markets?
Kane Biotech will join the Symposium on Advanced Wound Care in Las Vegas, taking place October 15-18, 2026. The firm will exhibit its revyve product line at Booth #544 and present new scientific findings.
Why it matters
The symposium serves as a key platform for the company to engage with clinicians and researchers while discussing clinical data. These interactions support plans to expand commercial reach and product awareness in the United States.
The company holds ISO 13485:2016 certification for its quality management systems. Its revyve Antimicrobial Wound Gel and Wound Gel Spray carry both U.S. FDA 510(k) clearance and Health Canada approval.
The players
Kane Biotech
A biotechnology company headquartered in Winnipeg that specializes in developing products to address bacterial biofilms.
Dr. Robert Huizinga
A leader in clinical research who represents the organization at scientific symposia.
The details
At its exhibit booth, the company will host meetings with current and potential distribution partners to discuss future market growth. Dr. Robert Huizinga will lead the scientific engagement by presenting three posters during the conference.
Timeline
October 15-18, 2026: The Symposium on Advanced Wound Care takes place in Las Vegas.
October 17, 2026: Dr. Robert Huizinga will present three scientific posters.
The Tech Race
Biotech firms increasingly rely on high-profile medical conferences to validate clinical efficacy against established market incumbents. This participation follows the established pattern of the Symposium on Advanced Wound Care as the primary nexus for innovation in wound healing technologies.
Clinicians and healthcare providers attending the event will have direct access to the latest clinical data regarding the revyve product line. These advancements could influence future treatment protocols for patients requiring antimicrobial wound care.
The takeaway
Advancing clinical validation remains a critical step for companies seeking to scale their medical technology portfolios. Healthcare professionals should look to upcoming research presentations to better understand how these specific antimicrobial gels integrate into current standard care.
Further reading
For more on industry developments, visit the Biotech section.
Live Poll
Do you believe healthcare companies are prioritizing patient access when expanding into new regional markets?
